Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Evaluation of the 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System in the Treatment of de Novo SFA Lesions

NCT02097082 is registered in ClinicalTrials.gov with 480 Biomedical as lead sponsor.

NCT NCT02097082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02097082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Evaluation of the 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System in the Treatment of de Novo SFA Lesions
Lead sponsor
480 Biomedical
Phase
Not applicable
Overall status
Completed
Start date
October 31, 2013
Completion date
May 31, 2017
Enrollment
28 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, intermittent claudication, peripheral arterial disease, vascular diseases